Teva recalls Parkinson's drug due to potency issues

Teva Pharmaceutical Industries Ltd. has recalled a batch of its generic Parkinson's combination drug treatment carbidopa/levodopa because it may contain too much of an active pharmaceutical ingredient. The Class II recall involved 3,881 bottles of 25 or 100mg carbidopa/levodopa. The voluntary recall is for the entire United States.

Teva also added that stability testing found that the product might be "superpotent." A class II recall as defined by the US Food and Drug Administration (FDA) means that use of a drug could cause temporary damage to health.

This is the third recall in less than five months by Israel-based Teva. In April, the company voluntarily recalled more than 1 million bottles of its generic of antidepressant Cymbalta. Then, in June, the company recalled nearly 130,000 cartons of its Tev-Tropin human growth hormone for children because there was a possibility that oil leaked into it.